Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
Forest Laboratories, now owned by AbbVie, shifted profits to Ireland for the antidepressant Lexapro, Gilead Sciences with its hepatitis C treatment Sovaldi and Regeneron with the eye drug Eylea.
Simplified Text
Forest Laboratories Gilead Sciences and Regeneron shifted profits to Ireland
Confidence Score
0.900
Claim Maker
The author
Context Type
News Article
Context Details
{
    "entities": [
        "Forest Laboratories",
        "Gilead Sciences",
        "Regeneron"
    ],
    "location": "Ireland",
    "strategy": "Shifting profits"
}
Subject Tags
Business Pharmaceuticals Tax
UUID
9fdae12a-b972-40f0-bf20-51d71ebafb2d
Vector Index
✗ No vector
Created
September 11, 2025 at 8:58 PM (2 days ago)
Last Updated
September 11, 2025 at 8:58 PM (2 days ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://www.nytimes.com/2025/08/14/health/pharma-tariffs-ireland-taxes.html
Tariffs Set to Hit Ireland, Where U.S. Drugmakers Play Tax Games
Pending
News
53 claims 🔥
2 days ago
https://www.nytimes.com/2025/08/14/health/pharma-tariffs-ireland-taxes.html

US drugmakers using Ireland for tax advantages face billions in tariffs on European medicines. Shifting production to the US increases costs. The situation highlights tax strategies and their impact.

Pharmaceutical Industry
International Trade
Taxation
Ireland
United States
Tariffs

Similar Claims (0)

Other claims identified as semantically similar to this one.

No similar claims found

This claim appears to be unique in the system.

Claim Management System - MVP